Neoplastic Process
Gilead’s Trodelvy Fails to Meet Primary Endpoint in Confirmatory Trial for Urothelial Cancer
Gilead Sciences, Trodelvy, urothelial cancer, TROPiCS-04 study, overall survival, antibody-drug conjugate, oncology, clinical trials, FDA approval
Gilead’s Trodelvy Fails to Meet Primary Endpoint in Lung Cancer Trial, but Shows Promise in Subgroup Analysis ###
Gilead Sciences, Trodelvy, Lung Cancer, ASCO, FDA, Clinical Trials, Oncology, Immunotherapy, Trop-2 Directed Antibody-Drug Conjugate
Novartis’ Scemblix Demonstrates Superior Efficacy and Safety in Newly Diagnosed Leukemia Patients ###
Novartis, Scemblix, Leukemia, Chronic Myeloid Leukemia (CML), Tyrosine Kinase Inhibitors (TKIs), Gleevec, American Society of Clinical Oncology (ASCO)
Early Detection and Personalized Treatment of Colorectal Cancer: The Promise of Whole Genome Sequencing-Based Circulating Tumor DNA Tracking” ###
Circulating tumor DNA (ctDNA), Whole genome sequencing (WGS), Colorectal cancer, Early detection, Personalized treatment, Adjuvant therapy, Molecular residual disease (MRD), Liquid biopsies
Regulatory Tracker: Lilly’s Retevmo Secures Pediatric Cancer FDA Nod ###
Retevmo, Eli Lilly, FDA approval, pediatric cancer, RET-altered, thyroid cancer, solid tumors, accelerated approval, LIBRETTO-121 trial, selpercatinib
Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy
Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.
BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront
BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany
AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup
AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer
J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks
J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.
ASCO24: Nimbus Unveils Promising Early Data for Next-Generation HPK1 Blocker in IO Therapies
ASCO24, Nimbus, Next-Generation IO Therapies, HPK1 Blocker, Early Data, Cancer Treatment, Immuno-Oncology, Clinical Trials.